Cargando…

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes

BACKGROUND: Adropin is a potent metabolic regulator of insulin sensitivity and glycolipid metabolism. The present study investigated the effects of sitagliptin on adropin and metabolic parameters in participants with newly diagnosed type 2 diabetes (T2D). METHODS: Thirty-five participants newly-diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qiu, An, Yu, Zhang, Lin, Zhang, Yuanying, Wang, Guang, Liu, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727947/ https://www.ncbi.nlm.nih.gov/pubmed/36476135 http://dx.doi.org/10.1186/s12902-022-01233-x

Ejemplares similares

Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wang, Qiu, et al.
Publicado: (2021)

Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease
por: Zhang, Lin, et al.
Publicado: (2023)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes
por: Shi, Chunhong, et al.
Publicado: (2019)

Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study
por: Xiao, Xiaoyan, et al.
Publicado: (2016)

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
por: Ji, Ming, et al.
Publicado: (2016)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016)

Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats
por: Zhang, Minchun, et al.
Publicado: (2019)

The Hepatokine Adropin Is Regulated by Estrogen
por: Stokar, Joshua, et al.
Publicado: (2021)

Comparison between newly diagnosed hypertension in diabetes and newly diagnosed diabetes in hypertension
por: Liu, Chang-Yuan, et al.
Publicado: (2019)

Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia
por: He, Mingqian, et al.
Publicado: (2021)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le, Tuan Dinh, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
por: Lavalle-González, F. J., et al.
Publicado: (2013)

Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes
por: Vaughan, Elizabeth M., et al.
Publicado: (2017)

Association of Serum Adropin Concentrations with Diabetic Nephropathy
por: Hu, Wenchao, et al.
Publicado: (2016)

Effectiveness and tolerability of perampanel monotherapy in children with newly diagnosed focal epilepsy
por: Zhao, Fen, et al.
Publicado: (2023)

The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: a cross‑sectional study
por: Wei, Wen, et al.
Publicado: (2022)

A Review of Adropin as the Medium of Dialogue between Energy Regulation and Immune Regulation
por: Zhang, Shuyu, et al.
Publicado: (2020)

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
por: Ji, Linong, et al.
Publicado: (2020)

Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes
por: Polkowska, Agnieszka, et al.
Publicado: (2019)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Lamotrigine monotherapy for newly diagnosed typical absence seizures in children()
por: Holmes, Gregory L., et al.
Publicado: (2008)

Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
por: Li, Na, et al.
Publicado: (2021)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Risk of hypertension in middle-aged and elderly participants with newly diagnosed type 2 diabetes and prediabetes
por: Sasaki, Nobuo, et al.
Publicado: (2020)

Regulation of Substrate Oxidation Preferences in Muscle by the Peptide Hormone Adropin
por: Gao, Su, et al.
Publicado: (2014)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Adropin deficiency worsens HFD-induced metabolic defects
por: Chen, Shi, et al.
Publicado: (2017)

Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study
por: Lin, Szu Han, et al.
Publicado: (2018)

Adropin and Irisin in Patients with Cardiac Cachexia
por: Kalkan, Ali Kemal, et al.
Publicado: (2018)

Adropin and Irisin in Patients with Cardiac Cachexia
por: Mansur, Alfredo José
Publicado: (2018)

Serum Adropin Levels in Patients on Hemodialysis
por: Boric-Skaro, Dijana, et al.
Publicado: (2021)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children
por: Qi, Cui-Juan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_26bi6pqtjv930ifn80kv8j72rd